Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310150 | 1.00 | TGFBR1 (0.43) | TGFBR1ECE1CA12CA1CA2 | |
| SCHEMBL16710264 | 1.00 | TGFBR1 (0.43) | TGFBR1ECE1CA12CA1CA2 | |
| SCHEMBL25897018 | 0.83 | TGFBR1 (0.38) | TGFBR1TDP1MMETSHR | |
| SCHEMBL12971591 | 0.83 | TGFBR1 (0.38) | TGFBR1TDP1MMETSHR | |
| SCHEMBL25897031 | 0.83 | TGFBR1 (0.38) | TGFBR1TDP1MMETSHR | |
| SCHEMBL13707923 | 0.82 | TGFBR1 (0.32) | TGFBR1ECE1 | |
| SCHEMBL21540295 | 0.82 | TGFBR1 (0.32) | TGFBR1ECE1 | |
| SCHEMBL21540179 | 0.81 | CA1 (0.35) | TGFBR1ECE1CA12CA1CA2 | |
| SCHEMBL21540225 | 0.81 | CA1 (0.35) | TGFBR1ECE1CA12CA1CA2 | |
| SCHEMBL19091163 | 0.80 | TGFBR1 (0.39) | TGFBR1ECE1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | TGFBR1 4167/4885ECE1 4647/4885CA12 3585/4885 |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | TGFBR1 4167/4885ECE1 4647/4885CA12 3585/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | TGFBR1 4167/4885ECE1 4647/4885CA12 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.